Archived Content
It is important to formulate goals for generating, collecting, and analyzing reimbursement evidence early in product development in order to ensure commercial success of a drug or a biologics. We are witnessing the emergence of a new integrated strategy while the biopharmaceutical industry is partnering up with payers to develop evidence of a product’s validity and utility as well as comparative clinical and cost effectiveness. The inaugural Generating Evidence for Reimbursement Decisions: Therapeutics conference is designed to bring together all major stakeholders in the field of evidence-based reimbursement, clinical development experts, reimbursement and government affairs specialists, health care economists and payers. The conference will be directly followed by Generating Evidence for Reimbursement Decisions: Diagnostics conference.
View Agenda
Achieving commercial success for an IVD product or device is becoming progressively more difficult in the current healthcare environment. The combination of tightening health care budget and launch of a large number of expensive molecular tests creates complications for payers to respond in traditional ways. Comprehensive clinical data and pharma-type clinical trials have increasingly become the condition of getting a test reimbursed. The inaugural Generating Evidence for Reimbursement Decisions: Diagnostics conference is designed to bring together major players the field of evidence-based reimbursement in diagnostics. The conference will be preceded by Generating Evidence for Reimbursement Decisions: Therapeutics conference.
View Agenda